Shanghai Fudan-zhangjiang Bio-pharmaceutical Co., Ltd.
Clinical trials sponsored by Shanghai Fudan-zhangjiang Bio-pharmaceutical Co., Ltd., explained in plain language.
Biopharmaceutical company developing innovative drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New hope for Hard-to-Treat cancers: first human trial begins
Disease control Recruiting nowThis early-stage study tests a new drug called FZ-AD005 in people with advanced solid tumors, especially small cell lung cancer and large cell neuroendocrine carcinoma. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 162 partic…
Phase: PHASE1 • Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New light therapy could fade Port-Wine stains
Disease control Recruiting nowThis study tests a treatment called Hemoporfin photodynamic therapy for port-wine birthmarks. It involves injecting a drug that is activated by green light to target the birthmark. 84 adults aged 18 to 75 will receive up to 3 treatment cycles to see which light dose works best an…
Phase: PHASE2 • Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for advanced cancer: first human trial of FZ-AD004 begins
Disease control Recruiting nowThis study tests a new drug, FZ-AD004, for the first time in people with advanced solid tumors that have spread or cannot be removed. The goal is to find a safe dose and see if it can shrink tumors. About 121 adults aged 18 to 75 will take part.
Phase: PHASE1 • Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC